BR9709066A - Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais. - Google Patents

Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.

Info

Publication number
BR9709066A
BR9709066A BR9709066-2A BR9709066A BR9709066A BR 9709066 A BR9709066 A BR 9709066A BR 9709066 A BR9709066 A BR 9709066A BR 9709066 A BR9709066 A BR 9709066A
Authority
BR
Brazil
Prior art keywords
defense mechanisms
against viral
host defense
mechanisms against
stimulating
Prior art date
Application number
BR9709066-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Gerard Tovey
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of BR9709066A publication Critical patent/BR9709066A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
BR9709066-2A 1996-05-09 1997-05-05 Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais. BR9709066A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
PCT/IB1997/000489 WO1997041883A1 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against viral challenges

Publications (1)

Publication Number Publication Date
BR9709066A true BR9709066A (pt) 2000-01-04

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9709066-2A BR9709066A (pt) 1996-05-09 1997-05-05 Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.
BR9709223-1A BR9709223A (pt) 1996-05-09 1997-05-05 Estimulação dos mecanismos de defesa do hospedeiro contra tumores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9709223-1A BR9709223A (pt) 1996-05-09 1997-05-05 Estimulação dos mecanismos de defesa do hospedeiro contra tumores.

Country Status (17)

Country Link
EP (2) EP0898478B1 (cg-RX-API-DMAC10.html)
JP (2) JP3806446B2 (cg-RX-API-DMAC10.html)
KR (2) KR100399499B1 (cg-RX-API-DMAC10.html)
CN (1) CN1154508C (cg-RX-API-DMAC10.html)
AR (2) AR007059A1 (cg-RX-API-DMAC10.html)
AT (2) ATE316793T1 (cg-RX-API-DMAC10.html)
AU (3) AUPN976596A0 (cg-RX-API-DMAC10.html)
BR (2) BR9709066A (cg-RX-API-DMAC10.html)
CA (2) CA2253908A1 (cg-RX-API-DMAC10.html)
DE (2) DE69735201T2 (cg-RX-API-DMAC10.html)
ES (2) ES2260794T3 (cg-RX-API-DMAC10.html)
ID (2) ID16885A (cg-RX-API-DMAC10.html)
IL (2) IL126972A0 (cg-RX-API-DMAC10.html)
NZ (2) NZ332690A (cg-RX-API-DMAC10.html)
TW (1) TW528599B (cg-RX-API-DMAC10.html)
WO (2) WO1997041883A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA973988B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
JP2003500113A (ja) * 1999-05-26 2003-01-07 ザ ブリガム アンド ウイミンズ ホスピタル、 インコーポレイテッド アルファ平滑筋アクチン活性を調節する薬剤の治療的使用
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
EP1591539B1 (en) 2004-04-29 2007-10-03 F. Hoffmann-La Roche Ag NS5A nucleoside sequence variation as a marker
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501236A (cg-RX-API-DMAC10.html) * 1980-08-22 1982-07-15
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
WO1992010207A1 (en) * 1990-12-14 1992-06-25 Schering Corporation Oral administration of alpha interferon to treat lung malignancies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
JP3806445B2 (ja) * 1996-05-09 2006-08-09 ファーマ・パシフィック・プロプライエタリー・リミテッド 治療方法

Also Published As

Publication number Publication date
JP3806444B2 (ja) 2006-08-09
IL126970A0 (en) 1999-09-22
EP0898478A1 (en) 1999-03-03
ATE316791T1 (de) 2006-02-15
BR9709223A (pt) 2000-12-12
JP2000504027A (ja) 2000-04-04
EP0898478B1 (en) 2006-02-01
KR100399501B1 (ko) 2003-12-18
AU2399297A (en) 1997-11-26
AU2710997A (en) 1997-11-26
WO1997041886A1 (en) 1997-11-13
KR20000010880A (ko) 2000-02-25
EP0956040B1 (en) 2006-02-01
ES2260794T3 (es) 2006-11-01
AU724190B2 (en) 2000-09-14
EP0956040A1 (en) 1999-11-17
DE69735204T2 (de) 2006-09-21
CN1218409A (zh) 1999-06-02
AR007058A1 (es) 1999-10-13
DE69735204D1 (de) 2006-04-13
WO1997041883A1 (en) 1997-11-13
KR100399499B1 (ko) 2003-12-18
ID16886A (id) 1997-11-20
DE69735201T2 (de) 2006-09-21
IL126972A0 (en) 1999-09-22
CN1154508C (zh) 2004-06-23
AU729514B2 (en) 2001-02-01
KR20000010882A (ko) 2000-02-25
TW528599B (en) 2003-04-21
AUPN976596A0 (en) 1996-05-30
NZ332690A (en) 2000-07-28
ATE316793T1 (de) 2006-02-15
EP0956040A4 (cg-RX-API-DMAC10.html) 1999-11-17
AR007059A1 (es) 1999-10-13
EP0898478A4 (en) 1999-05-26
ES2260790T3 (es) 2006-11-01
DE69735201D1 (de) 2006-04-13
CA2253902A1 (en) 1997-11-13
JP3806446B2 (ja) 2006-08-09
NZ332688A (en) 2000-07-28
ZA973988B (en) 1998-11-09
CA2253908A1 (en) 1997-11-13
ID16885A (id) 1997-11-20
JP2000504026A (ja) 2000-04-04

Similar Documents

Publication Publication Date Title
ID17768A (id) Metoda pengobatan
CA2116559A1 (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
AU2432995A (en) Biphenyl Mannopyranoside Compounds
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
BR0007743A (pt) Epa etìlico altamente purificado e outrosderivados de epa para distúrbios psiquiátricos eneurológicos
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
EP0850068A4 (en) LIPID EXTRACTS WITH ANTI-INFLAMMATORY ACTIVITY
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
BR9809951A (pt) Método para tratamento da obesidade
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
BR9709066A (pt) Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
BR9813549A (pt) Processo para prevenção e tratamento de miocárdio afetado por lesão
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
AU2139388A (en) Glycosaminoglycane for the treatment of diabetic microangiopathy
BR0315495A (pt) Composição para reduzir ingestão calórica
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
BR0109770A (pt) Uso de galantamina para o tratamento do comportamento neuropsiquiátrico associado com a doença de alzheimer
FR2707880B1 (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A , 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1855 DE 25/07/2006.